文献速递瓣膜外科

基于心脏瓣膜协作组超声心动图标准的牛心包二尖瓣生物瓣耐久性

Durability of bovine pericardial mitral bioprosthesis based on Heart Valve Collaboratory echocardiographic criteria.
PubMed 文献 · J Thorac Cardiovasc Surg · 2023-11-21

研究回顾1984至2016年648例植入Carpentier-Edwards PERIMOUNT心包生物瓣行二尖瓣置换的患者,前瞻性记录随访数据,平均随访7.8±5.4年。15年免于严重结构瓣 deterioration为64.0±3.6%,免于中/重度为52.1±3.6%,作者认为该瓣膜仍是可靠选择。

要点

  • 15年免于严重结构瓣 deterioration为64.0±3.6%,免于中/重度为52.1±3.6%。
  • 15年免于瓣膜外植(因结构瓣 deterioration)为69.3±3.5%。
  • 因结构瓣 deterioration外植的中位生存时间为21.7年,<65岁患者为16.1年。

核心结论

  • 基于心脏瓣膜协作组超声心动图标准,该瓣膜15年瓣膜相关事件率和结构瓣 deterioration率低,作者认为Carpentier-Edwards PERIMOUNT心包生物瓣仍是二尖瓣生物瓣的可靠选择。

研究设计与样本

  • 回顾性队列研究,1984至2016年648例患者(平均年龄68.8岁,53.9%女性)行二尖瓣置换术,排除多瓣膜置换,前瞻性记录临床、手术和随访数据,平均随访7.8±5.4年,共5043瓣年,随访完整率98.3%(11例失访)。

主要发现

  • 手术死亡率为4%,晚期死亡322例,线性化率为6.4%/瓣年,15年实际生存率为31.4±2.6%。
  • 植入时年龄、男性和术前纽约心脏协会III或IV级是影响晚期生存的显著危险因素。
  • 15年实际免于血栓栓塞为92.5±1.9%,免于大出血为93.8±1.7%,免于心内膜炎为93.2±1.3%,免于因结构瓣 deterioration外植为69.3±3.5%。
  • 因结构瓣 deterioration外植的中位生存时间全队列为21.7年,<65岁患者为16.1年。
  • 基于超声心动图数据,15年实际免于严重结构瓣 deterioration为64.0±3.6%,免于中/重度结构瓣 deterioration为52.1±3.6%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study evaluated the very long-term results of the Carpentier-Edwards pericardial bioprosthesis in the mitral position, with particular attention to structural valve deterioration based on echocardiographic criteria. METHODS: From 1984 to 2016, 648 patients (mean age 68.8 years; 53.9% female) underwent mitral valve replacement using the Carpentier-Edwards PERIMOUNT pericardial bioprosthesis. Multiple valve replacements were excluded. Clinical, operative, and follow-up data were prospectively recorded. The mean follow-up was 7.8 ± 5.4 years, for a total of 5043 valve-years. The follow-up data were 98.3% complete (11 patients lost). Structural valve deterioration was determined by strict echocardiographic assessment based on Heart Valve Collaboratory criteria. RESULTS: Operative mortality was 4%. A total of 322 late deaths occurred, for a linearized rate of 6.4%/valve-year. The actuarial survival rate at 15 years was 31.4 ± 2.6%. Age at implantation, male sex, and preoperative New York Heart Association class III or IV were significant risk factors affecting late survival. Actuarial freedoms from complications at 15 years were thromboembolism, 92.5 ± 1.9%; major bleeding, 93.8 ± 1.7%; endocarditis, 93.2 ± 1.3%; and explantation due to structural valve deterioration, 69.3 ± 3.5%. The median survival time for explantation due to structural valve deterioration was 21.7 years for the entire cohort (16.1 years for patients <65 years old). Based on echocardiographic data, actuarial freedom from severe and moderate/severe structural valve deterioration at 15 years were 64.0 ± 3.6% and 52.1 ± 3.6%, respectively. CONCLUSIONS: With low 15-year rates of valve-related events and structural valve deterioration based on Heart Valve Collaboratory echocardiographic criteria, the Carpentier-Edwards PERIMOUNT pericardial bioprosthesis remains a reliable choice for a mitral tissue valve.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Kermen S, Aupart A, Bonal M, et al. Durability of bovine pericardial mitral bioprosthesis based on Heart Valve Collaboratory echocardiographic criteria. J Thorac Cardiovasc Surg. 2023. PMID: 37981099. doi:10.1016/j.jtcvs.2023.11.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。